ERBB2 and breast cancer: Of these, trastuzumab, pertuzumab, and trastuzumab emtansine are HER2/ErbB2 receptor monoclonal antibodies approved for the treatment of metastatic HER2-positive breast cancer, and trastuzumab has been reported to inhibit RA synovial cell growth [40].